Oculis updates share capital for its existing at-the-market offering program

Rhea-AI Summary

Oculis Holding AG (Nasdaq: OCS; XICE: OCS) has issued 2,500,000 new registered ordinary shares with a nominal value of CHF 0.01 each from its existing capital band. These shares are currently recorded as treasury shares. The company's total registered shares now stand at 48,943,700, with approximately 43 million shares outstanding. Following this issuance, treasury shares represent 7.2% of the company's registered shares.

The new shares were issued in connection with an at-the-market (ATM) offering program established through a sales agreement with Leerink Partners on May 8, 2024. Under this program, Oculis may offer and sell ordinary shares worth up to $100 million through Leerink Partners as its sales agent. The newly issued shares have not been sold under the ATM program and are being held in reserve as treasury shares.

Positive

• Established ATM offering program providing access to up to $100 million in potential funding

Negative

• Potential future dilution of shareholders through ATM offering program of up to $100 million

ZUG, Switzerland, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company, has issued registered ordinary shares of the Company, each with a nominal value of CHF 0.01, issued out of existing capital band (Kapitalband), for an aggregate of 2,500,000 ordinary shares of the Company (the "New Shares"), recorded as treasury shares. The number of registered shares issued by the Company as per its Articles of Association is 48,943,700, of which approximately 43 million shares are outstanding. Following the issuance, the number of treasury shares (own shares) held by the Company is 7.2% of the Company’s registered shares.

The New Shares were issued in relation to the sales agreement between the Company and Leerink Partners LLC (”Leerink Partners”)  entered into on May 8, 2024, with respect to an at-the-market (“ATM”) offering program. Under the ATM offering program, the Company may offer and sell, from time to time at its sole discretion, ordinary shares of the Company having an aggregate offering price of up to $100 million through Leerink Partners as its sales agent. The New Shares have not been sold under the ATM offering program and will be held in reserve as treasury shares.

For more details on the ATM offering program, please refer to the Company’s previous press release dated May 17, 2024, and the Company’s SEC filings referenced therein.

For more information, please visit:
http://www.oculis.com

Oculis Contact:

Ms. Sylvia Cheung, CFO
sylvia.cheung@oculis.com 

Investor & Media Relations:

LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com 

1-212-915-2577

FAQ

How many new shares did Oculis (OCS) issue in January 2025?

Oculis issued 2,500,000 new registered ordinary shares with a nominal value of CHF 0.01 each.

What is the total number of outstanding shares for Oculis (OCS) after the January 2025 issuance?

Approximately 43 million shares are outstanding out of 48,943,700 total registered shares.

What is the maximum value of shares that can be sold under Oculis' (OCS) ATM program?

Under the ATM offering program, Oculis can offer and sell shares having an aggregate offering price of up to $100 million.

What percentage of Oculis' (OCS) registered shares are held as treasury shares after the January 2025 issuance?

Following the issuance, treasury shares represent 7.2% of the company's registered shares.